Cantor Fitzgerald initiated coverage of Tango Therapeutics with an Overweight rating.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX:
- Tango Therapeutics price target raised to $17 from $16 at H.C. Wainwright
- Navigating the AI Minefield: Tango Therapeutics’ Struggle with Security Risks and EU Regulations
- Tango Therapeutics reports Q4 EPS (32c), consensus (28c)
- Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024
- Rivian downgraded, Loweâs upgraded: Wall Street’s top analyst calls